Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China · Delayed Price · Currency is CNY 17.24
+0.14 (0.82%)
Feb 3, 2026, 3:00 PM CST
Cisen Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 492.8 | 508.91 | 521.34 | 349.96 | 334.15 | 438.78 |
Depreciation & Amortization | 218.4 | 218.4 | 233.89 | 230.25 | 219.49 | 159.98 |
Other Amortization | 6.54 | 6.54 | 1.96 | 0.98 | 3.14 | - |
Loss (Gain) From Sale of Assets | 0.14 | 0.14 | -0.59 | -0.97 | -0.27 | -0.17 |
Asset Writedown & Restructuring Costs | 56.66 | 56.66 | 74.27 | 13.06 | 21.34 | 29.53 |
Loss (Gain) From Sale of Investments | -72.83 | -72.83 | -33.74 | -15.56 | -66.42 | -96.41 |
Provision & Write-off of Bad Debts | -4.16 | -4.16 | 2.34 | 16.46 | -5.92 | -1.87 |
Other Operating Activities | 271.17 | 12.44 | 10.84 | 6.83 | -1.68 | 8.38 |
Change in Accounts Receivable | -20.82 | -20.82 | -336.44 | -542.34 | -113.29 | -221.35 |
Change in Inventory | -115.04 | -115.04 | -144.31 | 18.1 | -14.81 | 1.91 |
Change in Accounts Payable | 4.55 | 4.55 | 118.51 | 197.67 | -113.8 | 106.47 |
Change in Other Net Operating Assets | -25.94 | -25.94 | -4.92 | -18.73 | -9.26 | 1.64 |
Operating Cash Flow | 813.48 | 570.85 | 451.24 | 258.35 | 233.6 | 431.01 |
Operating Cash Flow Growth | 88.16% | 26.51% | 74.67% | 10.59% | -45.80% | 137.78% |
Capital Expenditures | -112.28 | -101.81 | -17.71 | -35.19 | -51.02 | -202.27 |
Sale of Property, Plant & Equipment | 2.37 | 0.49 | 0.76 | 0.01 | 0.49 | 1.22 |
Cash Acquisitions | - | - | 0.42 | - | - | - |
Investment in Securities | 16 | 16 | -408.36 | -274.13 | 289.99 | -84.04 |
Other Investing Activities | -403.07 | 63.57 | 46.77 | 36.23 | 88.02 | 238.05 |
Investing Cash Flow | -496.98 | -21.75 | -378.13 | -273.08 | 327.48 | -47.03 |
Short-Term Debt Issued | - | - | - | - | - | 330 |
Long-Term Debt Issued | - | 53.33 | 54 | 250 | 138 | 12.02 |
Total Debt Issued | 28.67 | 53.33 | 54 | 250 | 138 | 342.02 |
Short-Term Debt Repaid | - | - | - | - | - | -100.1 |
Long-Term Debt Repaid | - | -137.25 | -59.05 | -232.43 | -340.24 | - |
Total Debt Repaid | -73.42 | -137.25 | -59.05 | -232.43 | -340.24 | -100.1 |
Net Debt Issued (Repaid) | -44.75 | -83.92 | -5.05 | 17.57 | -202.24 | 241.92 |
Issuance of Common Stock | - | - | - | - | - | 42.73 |
Repurchase of Common Stock | - | - | - | - | - | -89.82 |
Common Dividends Paid | -203.37 | -304.56 | -156.13 | -139.54 | -120.73 | -279.99 |
Other Financing Activities | 14.64 | 23.85 | 27.38 | 230.16 | 4.54 | 1.2 |
Financing Cash Flow | -233.48 | -364.63 | -133.8 | 108.19 | -318.43 | -83.96 |
Foreign Exchange Rate Adjustments | 0.01 | 0.36 | 0.65 | 0.65 | -0.22 | -2.54 |
Net Cash Flow | 83.03 | 184.83 | -60.04 | 94.11 | 242.43 | 297.48 |
Free Cash Flow | 701.19 | 469.04 | 433.53 | 223.15 | 182.58 | 228.74 |
Free Cash Flow Growth | 91.32% | 8.19% | 94.27% | 22.22% | -20.18% | 193.67% |
Free Cash Flow Margin | 19.68% | 11.78% | 9.71% | 5.49% | 4.83% | 6.23% |
Free Cash Flow Per Share | 1.54 | 1.03 | 0.96 | 0.49 | 0.40 | 0.51 |
Cash Interest Paid | 0.45 | 0.45 | 0.6 | 0.44 | 0.38 | 0.44 |
Cash Income Tax Paid | 309.85 | 389.98 | 433.03 | 357.12 | 390.99 | 284.66 |
Levered Free Cash Flow | 590.65 | 499.47 | 443.54 | 283.19 | 137.89 | 350.92 |
Unlevered Free Cash Flow | 591.74 | 503.81 | 447.66 | 285.87 | 141.7 | 357.05 |
Change in Working Capital | -155.24 | -155.24 | -359.05 | -342.66 | -270.23 | -107.22 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.